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Abstract
Hepatitis B x antigen (HBxAg) is a trans-activating
protein that may be involved in hepatocarcinogenesis,
although few natural effectors of HBxAg that parti-
cipate in this process have been identified. To identify
additional effectors, whole cell RNA isolated from
HBxAg–positive and HBxAg–negative HepG2 cells
were compared by polymerase chain reaction select
cDNA subtraction, and one clone, upregulated gene,
clone 11 (URG11), was chosen for further character-
ization. Elevated levels of URG11 mRNA and protein
were observed in HBxAg–positive compared to
HBxAg–negative HepG2 cells. Costaining was ob-
served in infected liver (P< .01). URG11 stimulated
cell growth in culture (P< .01), anchorage-independent
growth in soft agar (P< .001), and accelerated tumor
formation (P< .01), and yielded larger tumors (P< .02)
in SCID mice injected subcutaneously with HepG2
cells. These data suggest that URG11 is a natural
effector of HBxAg that may promote the development
of hepatocellular carcinoma.
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Introduction
Chronic hepatitis B virus (HBV) infection is a major public
health problem worldwide because it is associated with
the development of hepatitis, cirrhosis, and hepatocellular
carcinoma (HCC) [1–3]. The mechanism(s) whereby HBV
causes HCC remains to be worked out, but increasing
evidence suggests that the viral contribution to HCC
involves persistently high levels of the virus-encoded X
antigen, or hepatitis B x antigen (HBxAg), in the liver of
chronically infected patients [4–7]. High levels of intra-
hepatic HBxAg expression directly correlate with the
intensity of liver disease [8,9]. HBxAg transforms cells
in vitro [10–12], whereas sustained high levels of HBxAg
in transgenic mice are associated with the development of
HCC [13–15], suggesting that HBxAg plays an important role
in the pathogenesis of this tumor type.
HBxAg has been identified as a potentially promiscuous
trans-activating protein [16,17]. HBxAg binds to and alters the
function of transcription factors such as OCT-1 [18], ATF-2
[19], CREB [19], TBP [20], a subunit common to RNA poly-
merases [21], and other elements of the transcriptional machi-
nery [22,23]. HBxAg may also repress gene expression by
binding to and inactivating the tumor suppressor, p53 [15,24],
and the senescence-related factor p55sen [25], as well as by
downregulating the expression of p21WAF1/CIP1/SDI1 [26] and
the translation initiation factor, sui1 [27], all of which negatively
regulate hepatocellular growth and survival. In addition, HBxAg
stimulates several cytoplasmic signal transduction pathways,
such as those involving NF-nB [28,29], AP-1 [30], MAPK
[31,32], and PI3K [33], that promote cell growth and/or promote
cell survival in the face of apoptotic stimuli. Since little is known
about the natural effectors of HBxAg that contribute to the
development of HCC, experiments were designed to identify
and characterize such effectors. In this report, it is shown that
HBxAg upregulates the expression of a unique gene (upregu-
lated gene, clone 11; URG11) that promotes hepatocellular
growth and tumorigenesis.
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Materials and Methods
Polymerase Chain Reaction (PCR) Select cDNA
Subtraction of RNA From HepG2X and HepG2CAT Cells
HepG2X and HepG2CAT cells were constructed, as
described [27]. HBxAg and CAT expressions were verified
prior to conducting this study [27]. RNA from each cell
line was then isolated and subjected to PCR select cDNA
subtraction using a commercial kit according to instruc-
tions provided by the manufacturer (Clontech, Palo
Alto, CA), as described [27]. The PCR fragments corre-
sponding to differentially expressed mRNAs were cloned,
sequenced, and compared to existing sequences within
GenBank. One of these differentially expressed PCR
fragments, designated as URG11, was chosen for further
characterization.
In Situ Hybridization (ISH)
To verify that URG11 was differentially expressed in
HepG2X compared to HepG2CAT cells, the URG11 cDNA
fragment obtained from PCR select cDNA subtraction was
used as a probe for ISH. ISH was carried out using the Oncor
ISH and digoxigenin/biotin detection kits (Oncor, Gaithers-
burg, MD), as described [27,34]. ISH was also carried out
using fresh frozen samples from tumor (HCC) and nontumor
livers collected from HBV carriers (see below).
Patient Samples
The HCC and surrounding nontumor liver tissues used
for analyses were obtained from three sets of patients.
Twenty-three paired tumor/nontumor samples came from
as many Chinese patients who had undergone surgery for
the removal of their tumors. Many patients lived in and
around Xi’an and were treated at the Fourth Military
Medical University. Other Chinese patients underwent
surgery at the Hepatobiliary Hospital of the Second Mili-
tary Medical University in Shanghai. Fourteen additional
paired tumor/nontumor samples were obtained from South
African patients. These tissues were usually obtained at
necropsy, although some were obtained as a result of
surgical resection at the University of Witwatersrand in
Johannesburg. Additional characteristics of these patients
have been published [27]. Formalin-fixed, paraffin-
embedded tissues, fresh frozen blocks, and  80jC
snap-frozen paired liver and tumor samples were collected
from most patients, used for diagnostic purposes, and
then made available for these studies. Analogous pieces
of uninfected human liver from two individuals were avail-
able to serve as controls. Other normal tissues from
uninfected individuals available for staining were from
the gastrointestinal mucosa, heart, placenta, ovary, brain,
kidneys, prostate, pancreas, and spleen. In addition, tumor
samples from 14 Chinese patients with colon cancer, from
10 patients with gastric cancer, from 7 patients with lung
cancer, and from 4 patients with breast cancer were used
as tumor controls. The use of all tissues for this work was
approved by the Institutional Review Board at the Thomas
Jefferson University.
Northern Blotting
Northern blotting was conducted as previously reported
[27]. Briefly, total RNA was extracted using the Qiagen
RNeasy RNA Kit (Qiagen, Valencia, CA). Twenty micro-
grams of total RNA from each sample was electrophoresed
on formaldehyde-denaturing agarose gels, and transferred
to nylon membranes (Schleicher and Schuell, Keene, NH).
The URG11 cDNA fragment obtained from PCR select
cDNA subtraction was radiolabeled with a[32P]dCTP
(NEN, Boston, MA) by random priming using the Prime-
A-Gene labeling kit (Promega, Madison, WI) and used for
hybridization under stringent conditions. The results were
detected by autoradiography and quantitated by phospho-
imaging. A probe for glyceraldehyde-3-phosphate dehydro-
genase (G3PDH) was used for the normalization of results
in each lane.
Cloning and Sequencing of Full-Length URG11 cDNA
To obtain the full-length clone of URG11, two gene-
specific primers were designed according to the sequence
of the URG11 cDNA fragment. The sense primer was
URG11-1p (5V-GGAGCTGGAGGAGATGAAGCACCGG-3V)
whereas the antisense primer was URG11-2p (5V-
GGCTCTCCCCTCGCAGAAATGTGGC-3V). These primers
were used in 5V and 3V RACE PCR with the Marathon cDNA
Amplification Kit according to enclosed instructions (Clon-
tech). Human placental cDNA was used as the template. The
PCR products were cloned into pT7blue vector (Novagen,
Madison, WI) and sequenced. The appropriate 3V and 5V
gene-specific fragments were then digested with EcoRI and
NotI and cloned into pcDNA3 (Invitrogen, San Diego, CA),
and the integrity of the full-length clone was verified by DNA
sequencing. The full-length sequence was analyzed for
homology to entries in GenBank.
Subcloning of HBxAg
The HBx gene obtained from the ayw sequence was
subcloned into pcDNA3, as described [27,34].
Preparation and Use of URG11 Antibodies
The full-length cDNA of URG11 was used to deduce the
corresponding amino acid sequence using the TRANSLATE
program. The amino acid sequence was then subjected to
analysis in the PEPTIDESTRUCTURE and PLOTSTRUC-
TURE programs to identify hydrophilic peptides that would
be suitable candidates for solid-phase peptide synthesis
[35]. Three peptides were made at the Kimmel Cancer
Center of the Thomas Jefferson University. Each of these
peptides was then coupled to keyhole limpet hemocyanin,
and New Zealand white rabbits were immunized (two rabbits
per peptide), as described [36]. Corresponding antibodies
were measured by specific enzyme-linked immunosorbent
assays [37]. A mixture of antibodies to peptide 2 (amino
acids 568–591, inclusive) and peptide 3 (amino acids
611–630, inclusive) was used at a dilution of 1:6000 each
for staining formalin-fixed, paraffin-embedded tissues, and at
a dilution of 1:10,000 each for staining fresh frozen samples.
Staining was otherwise carried out, as described [34].
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Controls included staining with preimmune serum in place of
primary antibodies, and preincubation of primary antibodies
with an excess (25 Ag) of the corresponding synthetic
peptide(s) prior to staining [37,38].
Western blot analysis was carried out, as described [27].
One hundred micrograms of protein from each sample was
analyzed by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) on 10% running gels and
transferred to PVDF membranes (Millipore, Bedford, MA).
The primary antibody consisted of a mixture of anti-URG11
from the three peptides (each at 1:600 dilution). For some
membranes, anti-HBx was used as the primary antibody, as
described [37,38]. The secondary antibody was horseradish
peroxidase goat antirabbit Ig (Santa Cruz Biotechnology,
Santa Cruz, CA). As a negative control, preimmune serum
was used in place of anti-URG11 or anti-HBx. As a positive
control, the peptides used for immunization were spotted
near the edge of the PVDF membranes following the transfer
step. The results were visualized using the enhanced chem-
iluminescence (ECL) detection system (Amersham,Uppsala,
Sweden). h-Actin was used as internal control for load-
ing using monoclonal mouse antihuman h-actin (Sigma,
St. Louis, MO) as primary antibody at a dilution of 1:10,000.
Construction of URG11 Over-expressing HepG2 and
Control Cells
Separate cultures of 1 106 HepG2 cells were trans-
fected with 10 Ag of pcDNA3-URG11, pcDNA3-HBx, or
pcDNA3 vector using the SuperFect Transfection Reagent
(Qiagen) as previously reported [27]. Cells were selected
in G418 (800 Ag/ml complete medium) for 4 weeks, and
resistant cultures were passaged without selecting colo-
nies. URG11 and HBxAg protein expressions were veri-
fied by Western blotting using anti-URG11 or anti-HBx,
respectively.
HBxAg Mutant Expressing HepG2 Cells
pcDNA3-HBx was used to make HBxAg mutants
lacking the carboxy-terminal 10 amino acids (HBx1–135),
the carboxy-terminal 40 amino acids (HBx1 – 105), the
amino-terminal 10 amino acids (HBx10–145), or the amino-
terminal 40 amino acids (HBx41 – 145), as previously
described [27]. Additional HBxAg mutants lacking amino
acid residues 42 to 77, inclusive (HBxML), or residues 78 to
115, inclusive (HBxMR ), were also constructed, as described
[27]. The mutant cDNA were verified by sequence analysis.
The polypeptides made from these various mutants were
verified by in vitro translation of each construct, and then
each construct was stably transfected into HepG2 cells.
Cultures were selected in G418 and passaged without selec-
tion of individual colonies in each case. Mutant expression
was assayed in cell lysates by Northern andWestern blotting.
Transient Transfection of HepG2 Cells
To determine whether HBxAg upregulates the expression
of URG11, 1 106 HepG2 cells were seeded overnight
into each of three 60-mm-diameter plates, and then transi-
ently transfected with 5 Ag of pcDNA3, pcDNA3-HBx, or
pcDNA3-URG11 using Superfect (Qiagen, Santa Clara, CA)
according to instructions provided by the manufacturer [27].
Cell lysates were prepared 48 hours post-transfection
and analyzed by SDS-PAGE. The levels of URG11 were
then determined by Western blotting using anti-URG11
antibodies.
Additional transient transfection experiments were per-
formed to determine the trans-activation function of each
HBxAg mutant. Five micrograms of each mutant was
cotransfected into separate cultures of HepG2 cells along
with 2 Ag of the reporter plasmid, pGL2-HIV-1-LTR, in
which expression of the luciferase gene is under the
control of the HBxAg–responsive HIV-LTR promoter.
Luciferase reporter gene activity was determined 48 hours
post-transfection. Additional details of this assay have
been previously published [27].
Growth Curves in Medium Containing 10% or 0% FCS
HepG2 cells stably transfected with pcDNA3, pcDNA3-
HBx, or pcDNA3-URG11 were seeded into six-well plates in
duplicate and grown in complete or serum-free medium. The
number of viable cells was determined at daily intervals for
up to 5 days by trypan blue staining. Cell viability was
independently determined using the modified tetrazolium
salt (MTT) assay (Cell Titer 96 Nonradioactive Cell Prolifer-
ation Assay; Promega). Growth curves from HepG2.2.15
cells [39] were generated in parallel for comparison.
Flow Cytometry
To assess the effect of URG11 on cell cycle, 1 105
HepG2-pcDNA3, HepG2-pcDNA3-HBx, or HepG2-pcDNA3-
URG11 cells were seeded into 60-mm-diameter plates in
complete medium overnight, placed in serum-free medium
for 48 hours to synchronize the cells, and then again in
complete medium. At 24, 48, and 72 hours, cells were
recovered, fixed, stained with propidium iodide, and sub-
jected to flow cytometry analysis for DNA content in the
FACS facility at the Thomas Jefferson University.
Growth of Cells in Soft Agar and Tumorigenicity in
Nude Mice
HepG2 cells stably transfected with pcDNA3, pcDNA3-
URG11, or pcDNA3-HBx were selected in G418 for 4 weeks.
To test for growth in soft agar, 1 104 cells/well were seeded
in triplicate into six-well plates, allowed to grow for 21 days,
and counted under code using an inverted microscope.
Colonies that were at least 0.5 mm in diameter were scored
as positive.
For tumorigenicity assays, three groups of 10 mice each
were injected subcutaneously at a single site with 5 106
cells (HepG2-pcDNA3, HepG2-pcDNA3-URG11, or HepG2-
pcDNA3-HBx) under code. Tumor onset was scored visually
and by palpitation at the sight of injection by two trained
laboratory personnel at different times on the same day.
Average tumor size was estimated by physical measurement
of the excised tumor at the time of sacrifice. With the
exception of mice with large tumor burdens, animals were
sacrificed 6 weeks postinjection. These tumors were verified
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Figure 1. Expression of URG11 in tissue culture cells and liver tissues was evaluated by ISH. ISH was performed in HepG2X (A) and HepG2CAT (B) cells.
(C) Northern blot hybridization was conducted with RNA isolated from HepG2CAT cells (lane 1) or HepG2X cells (lane 2). The relative amounts of URG11 mRNA
are indicated below each lane, and are based on normalization with G3PDH mRNA from the same lanes. (D–G) ISH for URG11 was performed in fresh frozen
sections from HCC (D), from infected liver surrounding the tumor (E), and from an uninfected liver (F). In panel G, ISH was performed on a consecutive section of
tissues from panel E with an irrelevant (SV40 DNA) probe. (H) Northern blot analysis was performed on RNA extracted from the nontumor liver of four patients
(N1–N4) and from the corresponding tumor from these same patients (T1–T4). Again, G3PDH in the same RNA samples was used for normalization.
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as being HCCs by hematoxylin and eosin (H&E) staining.
Blocks were available for further analysis.
Statistics
The relationship between HBxAg and URG11 signals
obtained by ISH and immunohistochemistry was determined
using 2 2 comparisons in the Fisher’s exact test. Statistical
significance was observed when P< .05. The mean differ-
ence between cell numbers (in culture), colonies (in soft
agar), or cell cycle phase for HepG2X, HepG2-pcDNA3-
URG11, and HepG2 vector (control) cells was determined
by the Student’s t-test. A significant relationship was indi-
cated when P< .05.
Results
Discovery and Cloning of the HBxAg Upregulated Gene,
URG11
Previous work established HepG2X and HepG2CAT
cells, and verified the expression of HBxAg or CAT, respec-
tively, in these cell lines [27]. Whole cell RNA was extracted
from each of these cell lines, and subjected to PCR select
cDNA subtraction, as described [27,34]. One of the cDNA
fragments upregulated in HepG2X compared to HepG2CAT
cells was 580 bases long but, on sequencing and GenBank
analysis, did not show homology with any known gene. To
check whether the RNA corresponding to the 580-bp frag-
ment was differentially expressed in HepG2X compared to
HepG2CAT cells, ISH was performed. The results show
hybridization in the cytoplasm of HepG2X cells (Figure 1A,
red-brown color) but little or no signal in HepG2CAT cells
(Figure 1B). Northern blot analysis showed only a single
band of about 3 kb in both cell lines (Figure 1C). However,
the levels of this RNA were 6.6F 0.4-fold higher in HepG2X
compared to HepG2CAT cells. Together, these results verify
the PCR select cDNA subtraction, and suggest that HBxAg is
associated with increased steady state levels of RNA from
this cellular gene.
To determine whether this gene is differentially expressed
in vivo, ISH was performed on fresh frozen liver and tumor
sections from HBV carriers, and in sections from uninfected
livers. In HCC tissues from 14 South African patients, ISH
signals were observed in nine (64%), whereas 12 of 23 (52%)
Chinese patients had detectable signals in tumors (Table 1).
The great majority of patients from both groups had faint
signals in less than 10% of HCC cells. An example of the
ISH results in a tumor from one of these patients,
indicated by the brown color in the cytoplasm, is pre-
sented in Figure 1D. In contrast, when surrounding non-
tumor liver tissues were analyzed by ISH in these same
carriers, 13 of 14 South African patients (93%) and all 23
Chinese patients (100%) analyzed had readily detectable
signals. These signals were observed in more than 30%
of the hepatocytes in most of the samples from each
group, suggesting that higher and more widespread
expression of this cellular gene occurred in nontumor
livers compared to HCC. Interestingly, when ISH was
performed on liver sections from two uninfected individu-
als, faint ISH signals were observed in less than 10% of
hepatocytes in both cases (Figure 1F ). When a consec-
utive section of nontumor liver tissues from the patient
presented in Figure 1E was analyzed by ISH using an
irrelevant probe, no signal was detected (Figure 1G),
verifying the specificity of hybridization. The relatively
strong ISH signal in nontumor compared to tumor tissues
was independently verified by Northern blot analysis. In
four cases, where large-enough pieces of tumor and
nontumor liver tissues were available and intact RNA
was obtained, the levels of RNA in nontumor tissues were
roughly two- to six-fold higher than in tumors when
normalized to the levels of G3PDH mRNA in the same
tissue extracts (Figure 1H ). Hence, a cDNA fragment
identified by PCR select cDNA subtraction in HBxAg–
positive compared to HBxAg–negative cell lines identified
a unique RNA whose expression is upregulated in the
liver of HBV carriers, but not in the tumor tissues from
these same patients, nor from the liver sections of two
uninfected individuals.
Based on these observations, the full-length cDNA clone
of URG11 was obtained using the RACE approach. An NCBI
blast search of the human genome showed that URG11
cDNA is located within human chromosome 11q11. A Gen-
Bank Fasta search showed that URG11 cDNA had 99.5%
Table 1. ISH Results for URG11 in Tumor/Nontumor Pairs from HCC Patients.
South African patients Uninfected livers
Case Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 2
T 1 0 0 1 2 0 1 1 1 0 1 0 1 1 – –
NT 2 1 1 2 3 2 2 2 3 3 3 0 2 3 1 1
Chinese patients
Case Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
T 1 1 1 0 0 1 0 1 1 0 1 1 0 0 0 2 1 0 1 0 0 1 0
NT 2 2 3 2 3 2 3 3 2 1 3 3 2 2 2 3 1 2 2 1 2 2 3
ISH staining is estimated as follows: 0 = no signal; 1 = ISH signal in <10% of cells; 2 = ISH signal in 10% to 25% of cells; 3 = ISH signal in 25% to 50% of cells; and
4 = ISH signal in >50% of cells. T = tumor; NT= nontumor.
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homology over a 3044-bp overlap with an existing entry
(AK056571) and an 87.7% homology in a 673-amino-acid
residue overlap within the same clone (Figure 2A). A more
thorough analysis of URG11 cDNA showed that it was 3074
bp long, with an open reading frame potentially encoding a
protein of 673 amino acids in length (spanning nucleotides
634–2652, inclusive) (Figure 2B). The putative protein prod-
uct is 70,463.48 Da and contains five von Willebrand factor
type-C (VWFC) repeats and one C-type lectin domain, as
revealed by GCG motifs analysis (Figure 2B). No other
structural features were identified.
Expression of URG11 and HBxAg in HCC and Surrounding
Nontumor Liver Tissues
If URG11 is upregulated by HBxAg in natural infection,
then there should be considerable costaining in tumor and/or
Figure 2. (A) Alignment of amino acid sequences for URG11 (bottom sequence) and AK056571 (top sequence). (B) cDNA sequence and predicted protein
structural features of URG11. The five VWFC repeat sequences are indicated in bold italic and span amino acid residues 121 to 157, 256 to 295, 306 to 342, 366 to
401, and 424 to 459. The C-type lectin domain is underlined and spans residues 366 to 387, which partially overlaps with the fourth VWFC repeat. Synthetic
peptides used to generate URG11-specific antisera span amino acids 254 to 269 (16 residues, peptide 1), 568 to 591 (24 residues, peptide 2), and 611 to 630
(20 residues, peptide 3) and are indicated by a double underline.
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nontumor liver cells. To test this, URG11 antisera were
raised in rabbits against three peptides within the URG11
sequence (Figure 2B). Consecutive sections of formalin-
fixed, paraffin-embedded tissues from the South African
and Chinese populations were then stained with anti-
URG11, anti-HBx, or preimmune serum. Among South Afri-
can patients, 10 of 14 (71%) had detectable URG11 protein
staining in tumor cells, as did 13 of 23 (57%) Chinese patients
(Table 2). When compared to the results of ISH using fresh
frozen samples from the same patients, both assays were
tightly correlated (P< .001). ISH and immunostaining like-
wise correlated in nontumor liver tissues from these two
groups of patients (Tables 1 and 2) (P< .001), indicating
cross-validation and suggesting that the upregulated
Figure 2. (Continued).
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expression of URG11 was at both the RNA and protein
levels. When the protein staining patterns of URG11 and
HBxAg were compared in consecutive sections from the
same patients, costaining was observed in 6 of 14 (42%)
tumor tissues from African patients, and in 8 of 23 (35%)
tumor tissues from Chinese patients. These relationships
Figure 2. (Continued).
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were not statistically significant (P> .2). However, when
URG11 and HBxAg staining patterns were compared in
surrounding nontumor liver tissues from these patients, cos-
tainingwas seen in 11 of 14 (79%) nontumor liver tissues from
African patients, and in 21 of 23 (91%) nontumor liver tissues
from Chinese patients (P < .01). URG11 staining was cyto-
plasmic (Figure3,AandD) andcostainingwithHBxAg (Figure
3, B and E) was common in liver samples from Chinese
(Figure 3, A and B) and South African (Figure 3, D and E)
patients. Staining with preimmune rabbit serum yielded no
detectable brown color (Figure 3, C and F ). In addition, no
browncolorwasobservedwhenstainingwasconducted in the
absence of secondary antibody, or when staining was con-
ducted after preincubation of the primary antibodies with the
synthetic peptides used for immunization (data not shown),
indicating that the staining was specific. URG11 staining was
present in the cytoplasmof hepatocytes from uninfected liver,
but this staining was oftenweak and only detectable in 10% to
20% of the cells (Figure 3G). This staining pattern was similar
to that observed in HCC cells. In contrast, a higher magnifi-
cation of an infected liver from an HCC patient with chronic
hepatitis showed cytoplasmic URG11 staining in most hep-
atocytes (Figure 3H), especially in those surrounding tumor
nodules.Collectively, these resultsdemonstrateconsiderable
costaining between URG11 and HBxAg in vivo.
Extrahepatic Distribution of URG11
Immunohistochemical staining was conducted in several
tumor types other than HCC and in a variety of normal
tissues from uninfected patients that were available from
archival paraffin blocks. Staining was observed in 10% to
50% of the cells from 13 of 14 patients (93%) who had colon
cancer, in 9 of 10 patients (90%) who had gastric cancer, in 6
of 7 patients (86%) with lung cancer, and in 4 of 4 patients
(100%) with breast cancer (data not shown). Relatively weak
staining was observed in surrounding nontumor cells in 9 of
14 patients (64%) with colon cancer, in 7 of 10 patients (70%)
with gastric cancer, in 3 of 4 patients (75%) with lung cancer
where nontumor lung tissues were available, and in 3 of 4
patients (75%) with breast cancer (data not shown). Weak or
trace amounts of staining were observed in the normal
gastrointestinal mucosa, heart, placenta, ovaries, brain,
kidneys, prostate, pancreas, and spleen (data not shown).
These results show that URG11 expression is upregulated in
a variety of tumors compared to peritumor and normal,
uninfected tissues, suggesting that it plays a role in the
pathogenesis of tumor types, in addition to HCC.
URG11 is Upregulated by HBxAg in HepG2 cells
Although the mechanisms whereby elevated URG11
expression in extrahepatic tissues remains to be explored,
the higher levels of URG11 in HepG2X compared to HepG2-
CAT cells (Figure 1), combined with HBxAg-URG11 costain-
ing in infected liver (Figure3), suggest thatURG11expression
is upregulatedbyHBxAg. To test this hypothesis,HepG2cells
were transiently transfected with pcDNA3, pcDNA3-HBx, or
pcDNA3-URG11. The results (Figure 4) show that the intro-
duction of HBxAg stimulates the expression levels of URG11
protein (lane 2),whereas pcDNA3doesnot (lane 1). The band
in lane 2 has both the size and immunoreactivity of URG11 in
lysates from HepG2 cells transiently transfected with
pcDNA3-URG11. These findings are consistent with the
hypothesis that URG11 is an effector of HBxAg.
Relationship Between HBxAg Trans-Activation and
Upregulated Expression of URG11
To address whether HBxAg trans-activation is responsi-
ble for the upregulated expression of URG11, HepG2 cells
were stably transfected with pcDNA3, pcDNA3-HBx, or
individual partial deletion mutants of HBxAg. Although cells
were selected in G418, assays were performed on cultures
that were passaged instead of on colonies chosen from each
culture. Initially, expressions of wild type and mutant HBxAg
polypeptides were verified by Western blotting in lysates
prepared from each of the stably transfected cell lines
(Figure 5A). The trans-activation function of each of these
mutants was then assayed by transient transfection of pGL2-
HIV-1-LTR [27]. The results verify that large deletions within
the HBx gene result in loss of trans-activation activity
(Figure 5B). When the levels of endogenous URG11 mRNA
Table 2. Immunohistochemistry for URG11 and HBxAg in Tumor/Nontumor Pairs from HCC Patients.
South african patients Uninfected livers
Case number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 2
T URG11 1 1 0 2 1 0 2 1 2 0 2 0 2 2
HBxAg 0 1 0 2 2 0 1 0 1 0 1 0 0 0
NT URG11 4 3 1 2 4 3 3 2 2 1 3 0 3 4 1 1
HBxAg 1 2 1 3 3 0 1 1 1 2 2 0 0 1 0 0
Chinese patients
Case number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
T URG11 1 1 2 0 0 2 0 2 1 0 1 1 0 0 0 2 1 0 1 0 0 1 1
HBxAg 1 0 0 1 0 1 0 2 1 0 1 0 0 1 0 2 0 0 0 0 0 2 2
NT URG11 3 2 3 1 3 2 2 3 2 1 3 3 2 3 3 2 2 0 3 2 3 3 4
HBxAg 3 1 1 2 1 2 1 3 1 0 2 1 1 1 2 3 2 0 1 2 1 2 2
Staining is estimated as follows: 0 = no signal; 1 = IHC signal in <10% of cells; 2 = IHC signal in 10% to 25% of cells; 3 = IHC signal in 25% to 50% of cells; and
4 = IHC signal in >50% of cells.
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Figure 3. Immunohistochemical staining for URG11 (A and D) and HBxAg (B and E) in liver sections from a Chinese (A–C) and a South African (D–F) patient with
HCC. Consecutive sections were also stained with preimmune serum in place of primary antibody (C and F) (original magnification, 100). URG11 staining in
uninfected liver (G) and at higher power of infected liver adjacent to tumor (H) (original magnification of G and H, 200).
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were assayed in each culture by Northern blot analysis, there
was a close correlation between HBxAg trans-activation
activity (Figure 5B) and elevated expression of URG11
mRNA (Figure 5C). The Northern blot of URG11 mRNA from
one of three experiments is presented in Figure 5D. These
results suggest that HBxAg transcriptionally trans-activates
URG11.
URG11 Stimulates Cell Growth in Tissue Culture
To study the effects of URG11 on cell growth, HepG2 cells
were stably transfected with pcDNA3-URG11 and the char-
acteristics of these URG11-over-expressing cells were com-
pared to those of HepG2X, HepG2CAT, and HepG2.2.15
cells, the latter of which stably replicates HBV [39]. Prelimi-
nary experiments were carried out to assess the levels of
URG11expression in these cell lines byWestern blotting. The
results show the presence of a single band reactive with
URG11 antisera at the expected value of approximately 68
kDa (Figure 6A). Compared to HepG2 vector–transfected
cells (lane 2), the levels of URG11proteinwere approximately
2.3-fold higher in HepG2.2.15 cells (lane 1), 5.8-fold higher in
HepG2X cells (lane 3), and 5.5-fold higher in HepG2-
URG11–over-expressing cells (lane 4). These results not
only verify URG11 expression, but also show that when
HBxAg is expressed in the context of viral replication (as in
HepG2.2.15 cells), URG11 expression is also elevated.
When the growth curves of these cell lines were compared
in medium containing 10% FCS, the curves for HepG2X and
HepG2-pcDNA3-URG11 cells were significantly higher than
control cells (P < .01 on days 4–8), whereas the growth curve
for Hep2.2.15 cells was between that of HepG2-pcDNA3-
URG11 and control cultures (Figure 6B). The same trends
were observed when cells were grown in serum-free medium
(Figure 6C). When the number of dead cells (attached + float-
ing) for each culture was determined, there were significantly
fewer cultures of HepG2X and HepG2-pcDNA3-URG11 cells
compared to controls (P< .03 on days 6–8) (Figure 6D).
Similar results were obtained using trypan blue (Figure 6D)
and MTT assays (data not shown). Hence, the protection
Figure 4. Western blot analysis of HepG2 cells transiently transfected with
pcDNA3 (negative control, lane 1), pcDNA3-HBx (lane 2), or pcDNA3-URG11
(positive control, lane 3).
Figure 5. Relationship between HBxAg trans-activation and upregulated expression of URG11 mRNA. Separate cultures of HepG2 cells were stably transfected
with pcDNA3, pcDNA3-HBx (HBx1 – 145), or one of the partially deleted mutants. (A) Western blot analysis of lysates prepared from HepG2 cells stably transfected
with pcDNA3 (lane 1), with full-length HBx (HBx1 – 145) (lane 2), HBx41 – 145 (lane 3), HBx11 – 145 (lane 4), HBx1 – 105 (lane 5), HBx1 – 135 (lane 6), XML (lane 7), or XMR
(lane 8). (B) Corresponding trans-activation activities of the various HBxAg polypeptides in HepG2 cells transiently transfected with pGL2-HIV-1-LTR. (C) Average
of Northern blot analysis of endogenous URG11 mRNA in three experiments (done in duplicate) from each of the HBxAg-expressing cell lines in (A). (D)
Actual Northern blot data of URG11 mRNA from one experiment. The numbered lanes in (A) correspond to the same numbered and aligned lanes in the
subsequent panels.
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against serum-induced apoptosis documented for HBxAg
[40] also seems to be a property of URG11.
To test whether HBxAg–stimulated cell growth is asso-
ciated with enhanced cell cycle, HepG2X, HepG2-pcDNA3-
URG11, and HepG2 vector control cells were synchronized
by serum starvation and then released by the addition of
medium containing 10% serum. The results showed that at
24 hours after the release of synchronized cultures, 32.2% of
HepG2-URG11 cells were in S-phase compared to 21.4% of
HepG2-pcDNA3 cells (P < .01) (Figure 7). Differences were
also observed in the fraction of cells in G2-phase, which was
24.2% for HepG2-pcDNA3-URG11 cells compared to 12.4%
for HepG2-pcDNA3 cells (P< .005). For HepG2-pcDNA3-
HBx cells, 36.6% of the cells were in S-phase at 24 hours
after the release from serum starvation, whereas 30.1%
were in G2-phase (Figure 7). These differences disappeared
by 48 hours after the release from serum starvation. Hence,
both URG11 and HBxAg stimulate cell cycle progression
significantly more than control cells.
URG11 Promotes Growth in Soft Agar and Tumor
Formation in SCID Mice
The observations that URG11 stimulated cell growth
(Figure 6) and cell cycle progression (Figure 7) suggested
that URG11 may contribute to tumor development. To
directly test this hypothesis, HepG2-pcDNA3, HepG2-
pcDNA3-HBx, and HepG2-pcDNA3-URG11 were seeded
into soft agar, and anchorage-independent growth was
determined after 3 weeks. HBxAg stimulated growth in soft
agar more than five-fold above background, whereas
URG11-overexpressing cells stimulated growth about three-
fold above background (P< .001) (Table 3). To test whether
URG11 stimulated tumor formation, the HepG2 lines tested
in soft agar were also evaluated for subcutaneous tumor
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Figure 6. (A) Western blot of URG11 in HepG2.2.15 (lane 1), HepG2-pcDNA3 (lane 2), HepG2-pcDNA3-HBx (lane 3), and HepG2-pcDNA3-URG11 (lane 4) using
anti-URG11 as the primary antibody. Equal amounts of cell lysate (25 lg) were loaded onto each lane. The numbers below the lanes are the relative amounts of
URG11 in the Western blot based on gel scanning and corrected by comparison with the corresponding b-actin control shown below each sample. (B and C)
Growth curves for HepG2-pcDNA3 (y), HepG2-pcDNA3-HBx (o), HepG2-pcDNA3-URG11 (n), and HepG2.2.15 cells (4) in medium containing 10% serum (B) or
0% serum (C) for the days indicated. (D) Percent of cells in each culture from panel C that were dead at each time point. Adherent cells were stained with trypan
blue at the indicated time points. The number of nonadherent (trypan blue [+]) cells was included in the count of dead cells at each time point. Experiments were
done in triplicate, and the curves in each case represent the average values from these experiments.
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formation in SCID mice. Both HBxAg and URG11 acceler-
ated the onset of tumor and the size of tumors that were
recovered 6 weeks after injection (Table 4). Hence, both
URG11 and HBxAg stimulate anchorage-independent
growth in soft agar and tumor formation in SCID mice.
Discussion
There is considerable evidence that sustained high levels of
HBxAg expression in the liver are associated with the devel-
opment of HCC [41]. The finding that HBxAg is a promiscu-
ous trans-activator [16,17] implies that HBxAg may
contribute to tumorigenesis by altering the patterns of host
gene expression in chronically infected liver. To identify
natural effectors of HBxAg, whole cell RNA from HepG2X
and HepG2CAT cells were subjected to PCR select cDNA
subtraction. One of the genes, URG11, whose expression is
upregulated by HBxAg in HepG2 cells (Figure 1, A–C)
verifies that the PCR select cDNA subtraction yielded a gene
that is differentially expressed. The additional findings that
URG11 is strongly expressed in the chronically infected liver
by ISH (Figure 1E, Table 1) and by protein staining (Figure 3,
Table 2) compared to tumor and uninfected liver tissues
(Figures 1 and 3, Tables 1 and 2) strongly suggests that
URG11 is upregulated in chronic HBV infection at the RNA
and protein levels. The additional finding that HBxAg expres-
sion in liver closely resembles that of URG11 (Figure 3,
Table 2) strongly suggests that URG11 is a natural effector of
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Figure 7. Flow cytometry of HepG2-pcDNA (panels A and B), HepG2-pcDNA3-URG11 (panels C and D), and HepG2-pcDNA3-HBx (panels E and F) cells at 24
hours (panels A, C, and E) and 48 hours (panels B, D, and F) after synchronization, followed by the addition of 10% FCS. The results shown here illustrate one of
the three independent analyses.
Table 3. Growth of URG11-Overexpressing HepG2 Cells in Soft Agar.
Cell line Average number
of colonies
Student’s
t-test (P )
HepG2-pcDNA3 8.2F 3.3 < .001
HepG2-pcDNA3-URG11 24F 4.3
HepG2-pcDNA3-HBx 43.7F 7.9
The average number of colonies is from three independent experiments
performed in triplicate.
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HBxAg in vivo. The finding that HBxAg transiently introduced
into HepG2 cells stimulates expression of URG11 at the
protein level (Figure 4) is consistent with the costaining data
in tissues, and further suggests that URG11 is an effector of
HBxAg. The observation that upregulated URG11 mRNA
levels correlate with HBxAg trans-activation activity
(Figure 5) provides at least a partial explanation for how
HBxAgmay upregulate URG11 in vivo. Hence, HBxAg trans-
activation triggers the increased expression of a cellular
protein in chronically infected liver that promotes hepatocel-
lular growth and survival, both of which are important for
tumor development.
If URG11 is an effector of HBxAg, it should demonstrate
some of the properties of HBxAg when over-expressed in
liver cells. The observation that URG11 stimulated HepG2
growth in serum-free medium (Figure 6C) suggests that
URG11, like HBxAg, promotes serum-independent survival.
This appears to be contributed by a URG11-mediated
increase in cell cycle progression (Figure 7) and by an
decrease in cell death (Figure 6D). These observations imply
that URG11 stimulates cell cycle regulatory pathways and/or
may be anti-apoptotic. Additional work will be necessary to
identify the pathways whereby URG11 alters cell growth and
survival and whether it is anti-apoptotic. Interestingly, other
HBxAg-upregulated cellular proteins, such as URG7 [34] and
URG4 [42], also stimulate cell growth and inhibit cell death.
This suggests that during chronic infection, multiple upregu-
lated genes are likely to cooperate in protecting infected
hepatocytes from immune-mediated destruction, thereby
promoting virus persistence and the carrier state. This coop-
eration may also promote the growth of infected over unin-
fected hepatocytes during liver regeneration, which may
partially explain the close correlation between HBxAg stain-
ing and the intensity of chronic liver disease [6–9].
The observation that URG11 promotes colony formation
in soft agar (Table 3) suggests that it plays an important role
in tumorigenesis. However, the promotion of colony forma-
tion by URG11 is weaker than that of HBxAg, suggesting that
other effectors of HBxAg, such as URG4 [42], may also
contribute. When URG11-over-expressing cells were eval-
uated for tumor formation, URG11 accelerated both the
onset of tumor and tumor size, as does HBxAg (Table 4).
These combined results suggest that URG11 promotes
tumor development. Given that HBxAg upregulates URG11
expression in preneoplastic tissues, URG11 likely mediates
some of the properties of HBxAg during the early stages of
hepatocarcinogenesis. As outlined above, elevated URG11
may directly contribute to the transformed phenotype, but it is
also possible that its upregulated expression in peritumor
tissues stimulates the release of growth factors that promote
tumor growth. Another HBxAg effector, URG4, also accel-
erates tumor onset and size [42], suggesting that these two
proteins cooperate in HBxAg–mediated transformation.
Future work will focus on the molecular-based mechanisms
whereby these URGs trigger transformation.
The finding of little HBxAg and URG11 in HCC cells, and
of little costaining in this compartment (Table 2), implies that
once autonomously growing tumors form, the expression of
these proteins is no longer rate-limiting. This suggests a
fundamental difference in the mechanisms that support
hepatocellular growth and survival in preneoplastic and neo-
plastic tissues. Many of the changes in preneoplastic cells
appear to be epigenetic and reversible in nature, whereas
many of the changes observed in tumor cells are genetic, the
latter of which include loss of heterozygosity and/or gene
amplification at many loci. In this context, URG11 is located
at chromosome 11q11, and that a gain in chromosome
11q13 is one of the changes documented in moderately to
poorly differentiated HCC [43,44]. In addition, it has been
proposed that gene amplification at 11q13 may involve the
upregulated expression of the bcl-1 oncogene and fibroblast
growth factor [44,45]. Interestingly, there is a recent report
showing that mice transgenic for fibroblast growth factor
develop HCC [46], suggesting that gene amplification in
this region may have functional consequences in tumor
development. For URG11, it is proposed that the HBxAg–
independent expression of URG11 in some tumors may be
associated with gene duplication involving URG11. This
would not only provide an explanation for why there is little
costaining in tumor cells, but would suggest that sustained
URG11 expression may also be important after the formation
of tumor nodules. The finding of a minority of HCCs with
upregulated URG11 expression in the absence of detectable
HBxAg (Table 2) is consistent with these ideas. This mech-
anism may not only be operative in HCCs, but also in many
other tumor types.
When the full-length nucleic acid sequence of URG11
was obtained, the deduced polypeptide sequence revealed
the presence of five von Willebrand domains and a single
C-type lectin domain (Figure 2B). These domains have been
observed in many other proteins and may participate in cell/
cell recognition and cell/matrix interaction, both of which are
important in cell fate decisions that distinguish normal liver
cells from tumor cells [47–52]. Moreover, C-type lectin
domains have been found in some proteins that appear to
regulate cell growth [53]. In this context, it will be of great
Table 4. Tumor Growth in HepG2 Cells Over-expressing URG11.
Cell line Onset of
tumor (days)
Student’s t-test
(tumor onset) (P)
Average size of
tumor (cm3)
Student’s t-test
(tumor size) (P )
HepG2 vector 41F 4 0.85F 0.3
HepG2-HBx 31F 4 < .03 1.5F 0.51 <.02
HepG2-URG11 23F 3 < .01 1.8F 0.55 <.02
The column to the right of ‘‘Onset of Tumor’’ lists the P values calculated from comparisons of HepG2-pcDNA3-HBx or HepG2-pcDNA3-URG11 cells culture to the
HepG2 vector controls. The column to the right of ‘‘Average Size of Tumor’’ compares the tumor sizes for each cell line with that of the HepG2 vector cells.
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interest to see, through the mutation or deletion of one or
more of these domains, how they contribute to the tumori-
genic properties of URG11 in cells over-expressing mutated
URG11 polypeptides.
Although HBxAg stimulates expression of URG11 and
other cellular genes, the responsible mechanisms have not
been elucidated. In this context, it has recently been shown
that HBxAg triggers the release of intracellular calcium from
the endoplasmic reticulum and/or mitochondria, which in turn
activates the cytosolic calcium-dependent proline-rich tyro-
sine kinase-2 (Pyk2) [54]. Pyk2 is an src family kinase that, in
turn, can activate ras signaling. Intracellular calcium release
is also known to activate other signaling molecules, such as
protein kinase C, calmodulin, calcineurin, nitric oxide syn-
thase, and protein kinase A [55]. It will be interesting to see
whether any of these pathways contributes to the HBxAg–
triggered alterations in host gene expression that contribute
to hepatocellular transformation on the molecular level.
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